news
Simplified HIV treatment options effective in major trial
The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
List view / Grid view
Janssen Inc.
news
FDA approves new dosing for Xarelto to reduce the risk of VTE
The FDA has approved the 10 mg once-daily dose of Xarelto, for reducing the continued risk of recurrent venous thromboembolism...
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
news
EMA approves Janssen’s Prezista continuous manufacturing line
The EMA has approved Janssen's continuous manufacturing (CM) with real-time release testing for the production of Prezista (darunavir)...
news
EMA to review Sandoz biosimilars adalimumab and infliximab
Sandoz announced that the EMA has accepted for regulatory review for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab)...
article
Treating multiple myeloma: An interview with Janssen
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
news
EC extends approval for Janssen’s daratumumab to include multiple myeloma patients
3 May 2017 | By Niamh Marriott, Junior Editor
The EC has granted approval to Janssen Daralex (daratumumab) for use in combination, for the treatment of adult patients with multiple myeloma (MM)...
news
NICE recommends Janssen’s Crohn’s Disease biological therapy
2 May 2017 | By Niamh Marriott, Junior Editor
NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease...
news
NICE does not recommend Janssen’s multiple myeloma drug
29 March 2017 | By Niamh Marriott, Junior Editor
NICE) has published new draft guidance not recommending daratumumab monotherapy (Darzalex, Janssen) to treat some people with multiple myeloma...
news
Janssen’s monoclonal antibody receives positive CHMP opinion to treat multiple myeloma
28 February 2017 | By Niamh Marriott, Digital Editor
If approved by the European Commission, daratumumab can be used for the treatment of adult patients with multiple myeloma...
news
Amorsa to collaborate with J&J on treatment-resistant depression therapy
5 January 2017 | By Niamh Marriott, Digital Editor
Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression...
news
EMA to review Janssen’s plaque psoriasis monoclonal antibody
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development...
news
Price drop means leukaemia CDF drug will be routinely available
2 December 2016 | By Niamh Louise Marriott, Digital Editor
Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance...
news
NICE does not recommend Janssen’s Waldenstrom’s macroglobulinaemia candidate
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute of Health and Care Excellence (NICE) has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia – a rare type of slow growing non-Hodgkin’s lymphoma.
news
Janssen submits EU application for rheumatoid arthritis drug
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
